# MIT Digital Health Startup Workshop

**March 26, 2021 11:00 am - 1:00 pm**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:00 AM | Welcome and Introduction  
Ariadna Rodenstein  
Events Leader, MIT Startup Exchange  
Peter Lohse  
Program Director, MIT ILP |
| 11:05 AM | Startup Lightning Talks and Q&A: Disease Diagnosis and Care  
nQ Medical: Cognition/motor digital biomarkers for neurological diseases  
Rich Bavasso  
CEO and Co-Founder, nQ Medical  
Rich Bavasso  
CEO and Co-Founder, nQ Medical |

Rich Bavasso is CEO and co-founder of nQ Medical Inc, a machine learning computational biomarker company leveraging personal devices to manage neuromotor diseases. nQ builds powerful, AI solutions to support the continuum of neurological health. Everyone has a unique typing signature. Research has revealed that the way we interact with our computers and mobile devices reveal with startling accuracy the presence of certain neuromotor diseases. This MIT discovered/Michael J. Fox Foundation validated artificial intelligence tool (neuroQWERTY) has opened a broad opportunity to better diagnose diseases, track disease progression, and monitor medication effectiveness and symptoms.

He is also Senior Executive Consultant, Digital Health and MedTech, Americas, for Scottish Development International. In this role, he supports the Scotland Government advising and assisting Scottish life sciences, MedTech, and digital health start-ups in with expansion into the US market. He also works with Fortune 500 US-based life sciences companies interested in expanding their footprint in the Scottish market and seeking to promote better and more productive UK-US collaborations.

Prior to nQ Medical, he founded and was CEO of RIMEDIO Inc, an eCommerce platform offering regulatory compliant content management and communications tools to consummate transactions between healthcare stakeholders.

Bavasso is also one of the early pioneers of use of digital media, devices and the web as tools to support Pharma/ MedTech sales and marketing strategies and tactics. Since 1999, he worked with top 25 Pharma/ MedTech clients globally to introduce the Closed Loop Marketing (CLM) function. In that role he set procedure and precedent in the areas of sales force effectiveness, business-rule driven content management, multichannel marketing, and mobile technology. As co-founder and former President of Exploria SPS LLC, he became the first major software vendor to introduce business rule controlled content management to Pharma's commercial sales operations. He was recognized as one of the top 100 influential people in Pharma by PharmaVOICE while in this role.

Prior to Exploria SPS, Mr. Bavasso served for sixteen years as CEO of Pharmedia Holdings LLC, and President of its INFLUENT Division, at the time one of the largest medical education companies in the world. He built Pharmedica holdings from its start as a meeting planning company in 1992, doubling its revenues each year until its sale in 2001. This growth included an ACCME accredited entity (Center for Medical Education LLC), a digital content division (INFLUENT LLC), and a call center (ContextMedicus LLC).

Mr. Bavasso is a licensed hospital administrator having served as Vice President at two health systems in New England. A graduate of Pepperdine University, Malibu, CA, with a BS in business administration, he received his MBA in health care management and finance from Bryant University.

A frequent speaker at industry conferences and events, Mr. Bavasso serves as an advocate for the industry in promoting digital conversation as integral to the various enterprise functions within the life sciences and the medical community.

| 11:05 AM | PathMaker: Pioneering neuromodulation for stroke/ALS  
Nader Yaghoubi  
President and CEO, PathMaker Neurosystems |
Nader Yaghoubi
President and CEO
PathMaker Neurosystems

Nader Yaghoubi, M.D., Ph.D. is President, CEO and Co-Founder of PathMaker Neurosystems. Dr. Yaghoubi has over 20 years of experience in the creation, operations and financing of life science companies. At PathMaker he serves as PI on a $5M NIH CREATE Device award from NIH, and is responsible for PathMaker being awarded several international prizes and grants. Prior to PathMaker Neurosystems, Dr. Yaghoubi founded and served as President and CEO of Symbiotic Biotherapies, a biotechnology company emerging from Harvard Medical School developing novel molecular therapeutics based on the human microbiome, and which was awarded over $5 million in NIH funding, did a corporate partnership and raised an equity financing round. Before PathMaker and Symbiotic, he was the first employee at BIND Biosciences (Nasdaq:BIND) and Selecta Biosciences (Nasdaq:SELB), where he worked with the MIT founders to launch the companies and rapidly take them operational. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and earlier completed an internship at Advent International. Prior to this, he was a Health Care Entrepreneurship Fellow at Boston University, where he worked with leading physicians to develop new healthcare-related businesses. Before his fellowship, he was a surgical resident in the Department of Surgery at Lenox Hill Hospital in New York. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued patents, received one of the University’s highest awards for dissertational research, and was the basis of a venture-backed biotechnology company focused on neuroscience. He is extensively involved in mentoring young companies, and has served as a mentor, advisor and reviewer with MBC’s MassCONNECT program, Mass Life Sciences Center programs, Springboard Venture Capital Forum and numerous university and international business plan competitions.

E25Bio: Rapid diagnostic COVID-19 tests paired with app
Bobby Brooke Herrera
Co-founder & Interim CEO

CareAcross: Personalized cancer coaching & remote monitoring
Thanos Kosmidis
Co-Founder & CEO

Thanos Kosmidis received his MEng in Computing from Imperial College (UK), his MS in Information Networking from Carnegie Mellon University (USA), and has been an Advanced Study Fellow at MIT’s Sloan School of Management (USA).

He has 20 years of experience in the technical and commercial divisions of high-tech companies in USA and Europe. His last post, which he left to build CareAcross, was that of deputy director at a large telecommunications’ firm strategic commercial planning department.

He has solid experience in managing multiple local and remote teams, including growing a team of 5 to reach 180 people across three countries and five timezones. He has led multimillion dollar projects from inception to delivery, and is experienced in the full lifecycle of products and services.

Mr Kosmidis is an active member of the international Health 2.0 organisation promoting the application of technology in healthcare, and a frequently invited speaker and presenter at international conferences in digital health.

Finally, Mr Kosmidis is serving as a Assembly Member for the European Commission’s “Mission on Cancer”, and as a technology expert for the European Commission Initiative on Breast Cancer (ECIBC), and the Quality Assurance Scheme Development Group (QASDG) in particular.

macro-eyes: AI to predict healthcare delivery globally
Benjamin Fels
macro-eyes
Benjamin Fels is the founder and CEO of macro-eyes: an AI company that makes crucial systems predictive. macro-eyes works for the governments of Sierra Leone, Tanzania, Mozambique, Nigeria, and the United States. macro-eyes works with the Bill & Melinda Gates Foundation, USAID, and the US Department of Defense. macro-eyes has a presence in countries across three continents.

Benjamin has particular expertise leading development of technology that learns in complex, real-world settings. He worked as a derivatives trader and managed quantitative, technology and profitable market teams in Chicago and London that built and ran trading systems that learned in real-time in financial markets. He advises the World Health Organization on the future of digital health and AI and the Financial Times published his op-ed on digital health and AI. He has been invited to speak to physician-scientists at the Kidney Research Institute, Penn Medicine, to clinical leaders in Alaska and Oregon, and to graduate students in economics at the University of Washington and Northwestern University.

Industry-Startup Panel

Zen Chu
Senior Lecturer
MIT Sloan

Rich Bavasso
CEO and Co-Founder, nQ Medical

Nigel Surridge
Research Fellow
Roche Diabetes Care Inc.

Jon Bloom
Co-Founder and CEO
Podimetrics
Anne Kim is cofounder and CEO of Secure AI Labs, which is based on her Media Lab graduate work at MIT with Professor Alex "Sandy" Pentland of the Human Dynamics Group. Secure AI offers a federated learning and blockchain solution for accessing siloed data from genomic and clinical trial data to corporate databases. Kim’s experience in computer science and molecular biology include genome-wide association studies, natural language processing for EHR, machine learning, and cyberbiosecurity work with the EFF, ACLU, and DEFCON. She sees accessibility to healthcare as a right, and believes that the interface between biology, healthcare policy, and technology is a promising way to achieve that mission.